Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 600x60px
Document › Details

Siemens AG. (11/6/14). "Press Release: Siemens to Sell Hearing Aid Business to EQT and Strüngmann Family". Berlin.

Organisations Organisation Siemens Audiologische Technik GmbH
  Group EQT (Wallenberg family) (Group)
  Organisation 2 EQT (Wallenberg family) (Group)
Products Product medical device
  Product 2 private equity
Index term Index term Siemens–SEVERAL: investment, 201411 acquisition of Siemens Audiology Solutions for €2.15b plus earn-out by EQT + Strüngmann family
Persons Person Requardt, Hermann (Siemens 200912 CEO Siemens Healthcare Sector)
  Person 2 Strüngmann, Thomas (Hexal founder + Biotech investor)

> Sale to EQT with Wallenberg family as anchor investor and to Strüngmann family as co-investor for €2.15 billion plus earn-out component

> Siemens reinvests €200 million in preferred equity

> Transaction closing expected in first quarter of calendar 2015

Siemens is selling Siemens Audiology Solutions to the investment company EQT and Germany's Strüngmann family of entrepreneurs as co-investor for €2.15 billion plus an earn-out component. Due to the very attractive offer made by the two investors, Siemens has decided not to further pursue preparations for the public listing it announced in May. "In the past years Siemens Healthcare has invested significantly in its audiology business. Both EQT with the Wallenberg family as anchor investor and the Strüngmann family have outstanding reputations and extensive experience in the healthcare sector. Not only is the transaction excellent from a financial perspective; we're also convinced that both investors have a clear growth strategy for further developing the hearing aid business over the long term," said Hermann Requardt, CEO of Siemens Healthcare and member of the Managing Board of Siemens AG. Siemens will remain invested in the hearing aid business with preferred equity of €200 million and benefit from future business successes. In addition, Siemens will have a seat on the board of the buyer group. Under the terms of the agreement, the new owners will also be allowed to continue using the Siemens product brand for the hearing aid business over the medium term.

"The Siemens audiology business has a very strong heritage for innovative, high quality products and we have been particularly impressed with the strong track record over the last couple of years. EQT is fully committed to supporting the management and employees in developing the business further," said Marcus Brennecke, Partner at EQT Partners.

EQT is a growth-oriented investment company managing around €22 billion in assets and with proven expertise in the healthcare and medical engineering sector. EQT is also the owner of LBX, one of the largest pharmacy chains in China's growth market. Germany's Strüngmann family of entrepreneurs is also known for its focus on long-term growth. In 1986, the family founded Hexal, which has since become Germany's leading provider of generic drugs.

In fiscal 2014, Siemens' globally active audiology business, with over 5,000 employees, generated revenue of €693 million and a reported EBITDA (earnings before interest, taxes, depreciation and amortization) of €145 million. The transaction will provide the audiology business with additional entrepreneurial freedom and flexibility while enabling it to continue its successful growth track of the last few years – with positive prospects for customers and employees. Agreements have been reached to ensure job security for the business's employees in Germany, who are working at locations in Erlangen and Herford. The transaction, which still requires regulatory approval, is expected to be closed in the first quarter of calendar year 2015 and will be financed in a solid manner, with roughly €1.1 billion of equity.

Siemens has been active in the audiology business for more than 100 years. The company launched first industrially produced hearing instrument, the Esha-Phonophor, onto the market in 1913. At the end of the 1950s, Siemens presented the first behind-the-ear hearing aid, followed by the first in-the-ear device in 1966 and the first digital hearing system in 1997. In 2004, Siemens was the first producer to introduce wireless technology that synchronized hearing aids in both ears. In 2012, the company, together with the University of Oldenburg, was awarded the German Future Prize by the German President for developing a binaural hearing system that enables communication between hearing aids in both ears. A few weeks ago, Siemens presented its new binax hearing aid platform, which is based on binaural technology, at the 59th International Congress of Hearing Aid Acousticians (EUHA) in Hanover, Germany, attracting major customer interest. The latest-generation of Siemens hearing aids is capable of sharing and exchanging audio signals in real time and can thus reproduce natural hearing processes in a binaural customization for both ears.

Siemens AG (Berlin and Munich) is a global technology powerhouse that has stood for engineering excellence, innovation, quality, reliability and internationality for more than 165 years. The company is active in more than 200 countries, focusing on the areas of electrification, automation and digitalization. One of the world's largest producers of energy-efficient, resource-saving technologies, Siemens is No. 1 in offshore wind turbine construction, a leading supplier of combined cycle turbines for power generation, a major provider of power transmission solutions and a pioneer in infrastructure solutions as well as automation, drive and software solutions for industry. The company is also a leading provider of medical imaging equipment – such as computed tomography and magnetic resonance imaging systems – and a leader in laboratory diagnostics as well as clinical IT. In fiscal 2014, which ended on September 30, 2014, Siemens generated revenue from continuing operations of €71.9 billion and net income of €5.5 billion. At the end of September 2014, the company had around 357,000 employees worldwide. Further information is available on the Internet at

This document contains statements related to our future business and financial performance and future events or developments involving Siemens that may constitute forward-looking statements. These statements may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. We may also make forward-looking statements in other reports, in presentations, in material delivered to shareholders and in press releases. In addition, our representatives may from time to time make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Siemens' management, of which many are beyond Siemens' control. These are subject to a number of risks, uncertainties and factors, including, but not limited to those described in disclosures, in particular in the chapter Risks in the Annual Report. Should one or more of these risks or uncertainties materialize, or should underlying expectations not occur or assumptions prove incorrect, actual results, performance or achievements of Siemens may (negatively or positively) vary materially from those described explicitly or implicitly in the relevant forward-looking statement. Siemens neither intends, nor assumes any obligation, to update or revise these forward-looking statements in light of developments which differ from those anticipated.

This document includes – in IFRS not clearly defined – supplemental financial measures that are or may be non-GAAP financial measures. These supplemental financial measures should not be viewed in isolation or as alternatives to measures of Siemens' net assets and financial positions or results of operations as presented in accordance with IFRS in its Consolidated Financial Statements. Other companies that report or describe similarly titled financial measures may calculate them differently.

Due to rounding, numbers presented throughout this and other documents may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.

This document is an English language translation of the German document. In case of discrepancies, the German language document is the sole authoritative and universally valid version. For technical reasons, there may be differences between the accounting records appearing in this document and those published pursuant to legal requirements.

Reference Number: PR2014110043COEN

Record changed: 2017-04-02


Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

More documents for EQT (Wallenberg family) (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top